#United States #Class Action #San Francisco #Securities Fraud #ADMA Biologics

Investors in ADMA Biologics Have Chance to Lead Class Action Lawsuit

In an alarming development for investors, ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a class action lawsuit concerning serious allegations of securities fraud. Hagens Berman, a well-known firm specializing in representing investors, has stepped in to inform affected parties about their opportunity to lead this legal action, which has a crucial deadline approaching on August 10, 2026. The lawsuit is poised to send ripples through the investment community as it targets significant misrepresentations made by the company, affecting the financial standings of many individuals.

Details of the Allegations

The lawsuit centers around allegations suggesting that ADMA Biologics engaged in misleading practices that artificially inflated their stock value. Key alleged wrongdoings include failing to disclose a related party transaction and utilizing controversial practices such as channel stuffing to create an illusion of heightened revenue. Moreover, it is claimed that the company lacked adequate internal controls over its financial reporting, leading to materially false statements regarding its business operations.

An official inquiry by Hagens Berman noted that these misrepresentations were uncovered through a series of corrective disclosures, resulting in severe financial repercussions for investors. The ramifications of these revelations became vividly clear following a report from Culper Research on March 24, 2026, which prompted a significant drop in ADMA's stock value—down by 31.6% within the span of two days as investors reacted to the insights regarding channel stuffing and undisclosed relationships with a distributor.

The Timeline of Events

A timeline of significant corrective events highlights the continued decline of investor confidence due to misleading information:

• - March 24, 2026: Culper Research publishes a report, leading to a 16.6% drop in stock price on that day and another 15.0% decline the following day, following further bad news regarding the company's revenue practices.
• - March 26, 2026: ADMA issued a press release attempting to mitigate concerns by acknowledging that they were assessing the claims made in the report. This came alongside a stock downgrade from Cantor Fitzgerald, which led to a further 13.9% decrease, closing at $8.29.

These instances reveal the substantial toll that the alleged misconduct has taken on investor trusts and stock valuations, leading to accumulated losses across the board.

What Affected Investors Can Do

For investors who have experienced losses related to ADMA Biologics, action is crucial. Hagens Berman urges individuals to report their experiences, particularly if they have knowledge pertinent to the case. Those who are affected or may possess relevant information are encouraged to reach out directly to the firm. Additionally, whistleblowers with undisclosed information about ADMA’s practices can explore the SEC Whistleblower Program, which offers financial incentives for those who contribute original information that results in successful sanctions against the company.

Conclusion

As the class action lawsuit against ADMA Biologics unfurls, impacted investors should act swiftly to protect their interests. The deadline of August 10, 2026, looms, and potential claimants must act decisively to join this fight for justice. Hagens Berman stands ready to help guide them through the legal maze in pursuit of accountability and fairness in the potentially flawed practices of ADMA Biologics.

For a deeper dive into the ongoing investigation or to seek further information about the ADMA case, interested parties can contact Hagens Berman directly or visit their website.